Guilin Sanjin Pharmaceutical Co Ltd (002275) - Total Assets

Latest as of September 2025: CN¥4.30 Billion CNY ≈ $629.19 Million USD

Based on the latest financial reports, Guilin Sanjin Pharmaceutical Co Ltd (002275) holds total assets worth CN¥4.30 Billion CNY (≈ $629.19 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore long-term investment intensity of Guilin Sanjin Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.

Guilin Sanjin Pharmaceutical Co Ltd - Total Assets Trend (2006–2024)

This chart illustrates how Guilin Sanjin Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 002275 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Guilin Sanjin Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Guilin Sanjin Pharmaceutical Co Ltd's total assets of CN¥4.30 Billion consist of 60.6% current assets and 39.4% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	24.8%
Accounts Receivable	CN¥645.36 Million	15.3%
Inventory	CN¥208.29 Million	4.9%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥141.55 Million	3.3%
Goodwill	CN¥5.70 Million	0.1%

Asset Composition Trend (2006–2024)

This chart illustrates how Guilin Sanjin Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Guilin Sanjin Pharmaceutical Co Ltd stock valuation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Guilin Sanjin Pharmaceutical Co Ltd's current assets represent 60.6% of total assets in 2024, an increase from 56.1% in 2006.
Cash Position: Cash and equivalents constituted 24.8% of total assets in 2024, up from 23.7% in 2006.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2006.
Asset Diversification: The largest asset category is accounts receivable at 15.3% of total assets.

Guilin Sanjin Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Guilin Sanjin Pharmaceutical Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	USA	$15.42 Trillion
GALDERMA GROUP AG NYSE:GALDY	USA	$13.39 Billion
Jiangsu Hengrui Medicine Co Ltd SHG:600276	China	CN¥68.33 Billion
Takeda Pharmaceutical Company Limited F:TKDA	Germany	€15.41 Trillion
Ajanta Pharma Limited NSE:AJANTPHARM	India	Rs56.72 Billion
Kangmei Pharmaceutical Co Ltd SHG:600518	China	CN¥13.68 Billion
Cronos Group Inc TO:CRON	Canada	CA$1.18 Billion
Guizhou Bailing Group Pharmaceutical Co Ltd SHE:002424	China	CN¥5.95 Billion

Guilin Sanjin Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	3.13	3.80	4.04
Quick Ratio	2.84	3.37	3.71
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥1.71 Billion	CN¥1.67 Billion	CN¥1.79 Billion

Guilin Sanjin Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Guilin Sanjin Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	2.62
Latest Market Cap to Assets Ratio	0.27
Asset Growth Rate (YoY)	7.5%
Total Assets	CN¥4.23 Billion
Market Capitalization	$1.15 Billion USD

Valuation Analysis

Below Book Valuation: The market values Guilin Sanjin Pharmaceutical Co Ltd's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Guilin Sanjin Pharmaceutical Co Ltd's assets grew by 7.5% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)

The table below shows the annual total assets of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024.

Year	Total Assets	Change
2024-12-31	CN¥4.23 Billion ≈ $619.31 Million	+7.52%
2023-12-31	CN¥3.94 Billion ≈ $575.97 Million	-0.73%
2022-12-31	CN¥3.96 Billion ≈ $580.19 Million	-3.20%
2021-12-31	CN¥4.10 Billion ≈ $599.35 Million	+5.50%
2020-12-31	CN¥3.88 Billion ≈ $568.10 Million	+13.66%
2019-12-31	CN¥3.42 Billion ≈ $499.81 Million	+0.28%
2018-12-31	CN¥3.41 Billion ≈ $498.42 Million	+5.47%
2017-12-31	CN¥3.23 Billion ≈ $472.59 Million	+12.53%
2016-12-31	CN¥2.87 Billion ≈ $419.95 Million	+3.99%
2015-12-31	CN¥2.76 Billion ≈ $403.83 Million	-0.86%
2014-12-31	CN¥2.78 Billion ≈ $407.33 Million	+3.51%
2013-12-31	CN¥2.69 Billion ≈ $393.51 Million	+8.21%
2012-12-31	CN¥2.49 Billion ≈ $363.66 Million	+12.91%
2011-12-31	CN¥2.20 Billion ≈ $322.07 Million	+11.09%
2010-12-31	CN¥1.98 Billion ≈ $289.92 Million	-3.91%
2009-12-31	CN¥2.06 Billion ≈ $301.71 Million	+76.87%
2008-12-31	CN¥1.17 Billion ≈ $170.59 Million	+8.06%
2007-12-31	CN¥1.08 Billion ≈ $157.87 Million	+29.70%
2006-12-31	CN¥831.81 Million ≈ $121.72 Million	--

About Guilin Sanjin Pharmaceutical Co Ltd

SHE:002275 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.15 Billion

CN¥7.89 Billion CNY

Market Cap Rank

#8518 Global

#2147 in China

Share Price

CN¥13.43

Change (1 day)

+0.07%

52-Week Range

CN¥13.35 - CN¥17.38

All Time High

CN¥19.61